BioRestorative Therapies, Inc.
BRTX
$2.74
-$0.06-2.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -7.20% | -54.73% | -94.95% | 240.40% | -28.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.20% | -54.73% | -94.95% | 240.40% | -28.57% |
| Cost of Revenue | 155.17% | -51.52% | -41.76% | 33.85% | -- |
| Gross Profit | -28.51% | -55.00% | -99.44% | 256.66% | -36.86% |
| SG&A Expenses | -32.41% | 18.30% | 6.34% | 25.21% | -29.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.46% | 40.66% | 47.62% | 41.08% | 16.61% |
| Operating Income | 29.57% | -42.20% | -62.18% | -33.88% | -16.99% |
| Income Before Tax | 59.65% | -96.05% | -178.39% | 34.06% | -140.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 59.65% | -96.05% | -178.39% | 34.06% | -140.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.65% | -96.05% | -178.39% | 34.06% | -140.17% |
| EBIT | 29.57% | -42.20% | -62.18% | -33.88% | -16.99% |
| EBITDA | 29.91% | -42.91% | -63.33% | -34.34% | -16.95% |
| EPS Basic | 80.98% | -63.45% | -148.01% | 38.73% | -91.73% |
| Normalized Basic EPS | 80.98% | -3,640.36% | -148.01% | 38.73% | -91.73% |
| EPS Diluted | 80.98% | -63.45% | -148.01% | 38.73% | -91.73% |
| Normalized Diluted EPS | 80.98% | -3,640.36% | -148.01% | 38.73% | -91.73% |
| Average Basic Shares Outstanding | 112.11% | 19.94% | 12.24% | 7.61% | 25.27% |
| Average Diluted Shares Outstanding | 112.11% | 19.94% | 12.24% | 7.61% | 25.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |